severe or diffuse PAVMs. 2 , 3 However, a cohort study of 219 consecutive patients with HHT and PAVMs showed no clear relationship between the risk of brain abscess or stroke with markers of PAVM severity, including diameter of the largest feeding vessel or degree of right-to-left shunt. 4 As mentioned by Dr Salerno, a second potential mechanism has to do with the local microenvironment at the pulmonary vasculature level. The extensive accumulation of pulmonary intravascular macrophages that adhere to the pulmonary endothelium in animal models of biliary cirrhosis is very well known and is believed to be a compensatory mechanism due to the dramatic decrease in the phagocytic capacity of the liver that allows circulating bacteria to enter the pulmonary circulation. 5 If a similar phenomenon occurs in humans, we speculate that the increased intravascular macrophage activity could play a role in better bacterial clearance, despite shunting. A third potential mechanism is the common use of antibiotic therapy to prevent spontaneous bacterial peritonitis in patients with HPS compared with patients with HHT. Long-term antibiotic use in these patients may help to further reduce transient bacteremia, decreasing the risk of brain abscesses. Furthermore, it has been shown in experimental models that the use of antibiotics, such as norfloxacin (commonly prescribed in patients with cirrhosis to prevent spontaneous bacterial peritonitis), reduces the severity of intrapulmonary shunting by decreasing the nitric oxide production of the pulmonary intravascular macrophages. 6 We agree with Dr Salerno that further prospective studies which include the reporting of cerebrovascular events in the setting of HPS are needed to elucidate this important clinical question. 
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Evidence Rofl umilast Reduces Severe Exacerbations ?
To the Editor:
In the May 2013 issue of CHEST , Wedzicha et al 1 conclude in the abstract section of their article that the reduction in severe exacerbations leading to hospitalization or death associated with rofl umilast was similar between subgroups defi ned as infrequent and frequent exacerbators. This is misleading, as it implies there is a reduction in severe exacerbations associated with rofl umilast. The datasets published in this article report the number of patients who experienced infrequent exacerbations (zero or one) or frequent exacerbations (two or more) with rofl umilast vs placebo. Although listed as a study end point, there are no data presented illustrating the number of patients experiencing severe exacerbations to support the claim that there is a reduction in severe exacerbations associated with rofl umilast. The authors state that in patients defi ned as frequent exacerbators in the year prior to study, 3.4% in the rofl umilast and 6.5% in the placebo group had two or more severe exacerbations after 1 year. 1 This approached, but did not reach, statistical difference ( P 5 .0516). 1 They do not, however, include severe exacerbation data in the placebo and rofl umilast groups at year 0 to support there being a reduction in severe exacerbations at 1 year. From the data presented, all that can be concluded is that there is no difference in the number of frequent exacerbator phenotype patients who experience two or more severe exacerbations while given rofl umilast when compared with placebo.
In the pivotal study by Calverley et al 2 there was a reduction in the combined end point of moderate/severe exacerbations in rofl umilast compared with placebo (1.14 vs 1.37, P , .0003). 2 However, a closer look at the data reveals that there was no difference in severe exacerbation rate (0.12 vs 0.15, P 5 .1334), indicating that the improvement in the combined end point is truly an improvement in the rate of moderate exacerbation alone. 2 I believe it is important that the effect of rofl umilast on severe exacerbations of COPD be represented accurately by Wedzicha et al, 1 as previously published data do not provide evidence that rofl umilast prevents severe exacerbations of COPD .
Timothy Coyle , DO Farmington, CT

Response
We would like to thank Dr Coyle for his interest in our recent article in CHEST. 1 We apologize that the sentence included in the abstract, stating that the reduction in severe exacerbations lead ing to hospitalization/death was similar between subgroups, lacked clarity.
We presented pooled post hoc data on the effects of a 1-year treatment with rofl umilast or placebo on exacerbation frequency in subsets of patients with either frequent (two or more) or infrequent (only one) exacerbations in the previous year (year 0). Among frequent exacerbators, rofl umilast signifi cantly lowered the risk for those remaining in the frequent exacerbator group by 20% compared with placebo (risk ratio [RR], 0.799; P 5 .0148). When looking at the proportion of patients with frequent severe exacerbations (two or more) at year 1 in the subgroup of frequent exacerbators, the risk reduction with rofl umilast vs placebo was 46.6%; however, the effect missed statistical signifi cance (RR, 0.534; 95% CI, 0.28-1.00; P 5 .0516). The wide CI is mainly attributable to the small subgroup experiencing severe COPD exacerbations, that is, 3.4% (rofl umilast) and 6.5% (placebo) of the frequent exacerbator subgroup. Similarly, the 18% reduction of severe COPD exacerbations observed with rofl umilast vs placebo in two 1-year studies failed to meet statistical signifi cance (RR, 0.82; 95% CI, 0.63-1.06; P 5 .1334). 2 Bateman et al 3 investigated the effects of rofl umilast on the number of hospitalizations resulting from severe COPD exacerbations based on data from the same two 1-year trials using negative binomial regression analysis. Because of the small number of severe COPD exacerbations (annual rate per patient, 0.16 and 0.126 for placebo and rofl umilast, respectively), this statistical analysis is considered more appropriate than the Poisson regression model presented in the article by Calverley et al. 2 Compared with placebo, rofl umilast decreased the rate of hospitalizations resulting from severe COPD exacerbations by 2 21.6% (RR, 0.784; 95% CI, 0.619-0.993; P 5 .0439).
In conclusion, data suggest a consistent trend with borderline statistical signifi cance in the reduction of severe COPD exacerbations with rofl umilast vs placebo in patients with severe to very severe COPD. We express our sincerest respect to Dr Coyle for having initiated this discussion.
